Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, Chao‐Hua Chiu et autres
Introduction EGFR -mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed in EGFR- mutant NSCLC after progression with EGFR tyrosine kinase inhibitors …
au, tw (code pays fourni par la source)
1 citation
JTO Clinical and Research Reports